-
1
-
-
79959936188
-
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants
-
[1] Danaei, G., Finucane, M.M., Lu, Y., Singh, G.M., Cowan, M.J., Paciorek, C.J., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants. Lancet 378 (2011), 31–40.
-
(2011)
Lancet
, vol.378
, pp. 31-40
-
-
Danaei, G.1
Finucane, M.M.2
Lu, Y.3
Singh, G.M.4
Cowan, M.J.5
Paciorek, C.J.6
-
2
-
-
2342466734
-
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030
-
[2] Wild, S., Roglic, G., Green, A., Sicree, R., King, H., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27 (2004), 1047–1053.
-
(2004)
Diabetes Care
, vol.27
, pp. 1047-1053
-
-
Wild, S.1
Roglic, G.2
Green, A.3
Sicree, R.4
King, H.5
-
3
-
-
84925489733
-
Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
[3] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 58 (2015), 429–442.
-
(2015)
Diabetologia
, vol.58
, pp. 429-442
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
Diamant, M.4
Ferrannini, E.5
Nauck, M.6
-
4
-
-
0036158954
-
Biological actions and therapeutic potential of the glucagon-like peptides
-
[4] Drucker, D.J., Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 122 (2002), 531–544.
-
(2002)
Gastroenterology
, vol.122
, pp. 531-544
-
-
Drucker, D.J.1
-
5
-
-
34447267513
-
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis
-
[5] Amori, R.E., Lau, J., Pittas, A.G., Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298 (2007), 194–206.
-
(2007)
JAMA
, vol.298
, pp. 194-206
-
-
Amori, R.E.1
Lau, J.2
Pittas, A.G.3
-
6
-
-
44949231427
-
Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus
-
[6] Richter, B., Bandeira-Echtler, E., Bergerhoff, K., et al. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. Cochrane Database Syst Rev, 2008, CD390067.
-
(2008)
Cochrane Database Syst Rev
, pp. CD390067
-
-
Richter, B.1
Bandeira-Echtler, E.2
Bergerhoff, K.3
-
7
-
-
34250212715
-
Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
-
[7] Nissen, S.E., Wolski, K., Effect of Rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007), 2457–2471.
-
(2007)
N Engl J Med
, vol.356
, pp. 2457-2471
-
-
Nissen, S.E.1
Wolski, K.2
-
8
-
-
85011268105
-
Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes
-
[8] U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008.
-
(2008)
-
-
U.S. Department of Health and Human Services, Food and Drug Administration,1
-
9
-
-
84902545306
-
Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence?
-
[9] Boussageon, R., Gueyffier, F., Cornu, C., Effects of pharmacological treatments on micro- and macrovascular complications of type 2 diabetes: what is the level of evidence?. Diabetes Metab 40 (2014), 169–175.
-
(2014)
Diabetes Metab
, vol.40
, pp. 169-175
-
-
Boussageon, R.1
Gueyffier, F.2
Cornu, C.3
-
10
-
-
84944800184
-
Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
-
[10] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
-
(2015)
N Engl J Med
, vol.373
, pp. 2117-2128
-
-
Zinman, B.1
Wanner, C.2
Lachin, J.M.3
Fitchett, D.4
Bluhmki, E.5
Hantel, S.6
-
11
-
-
70049099036
-
Assessing risk of bias in included studies
-
J.P.T. Higgins S. Green Cochrane collaboration
-
[11] Higgins JPTAD, Sterne, J.A.C., Assessing risk of bias in included studies. Higgins, J.P.T., Green, S., (eds.) Cochrane handbook for systematic reviews of interventions. Version 5.1.0, 2011, Cochrane collaboration.
-
(2011)
Cochrane handbook for systematic reviews of interventions. Version 5.1.0
-
-
Higgins JPTAD1
Sterne, J.A.C.2
-
12
-
-
84902551303
-
Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal
-
[12] Scheen, A.J., Charbonnel, B., Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal. Diabetes Metab 40 (2014), 176–185.
-
(2014)
Diabetes Metab
, vol.40
, pp. 176-185
-
-
Scheen, A.J.1
Charbonnel, B.2
-
13
-
-
79959559653
-
Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies
-
[13] Elashoff, M., Matveyenko, A.V., Gier, B., Elashoff, R., Butler, P.C., Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1–based therapies. Gastroenterology 141 (2011), 150–156.
-
(2011)
Gastroenterology
, vol.141
, pp. 150-156
-
-
Elashoff, M.1
Matveyenko, A.V.2
Gier, B.3
Elashoff, R.4
Butler, P.C.5
-
14
-
-
84896731936
-
Pancreatic safety of incretin-based drugs—FDA and EMA assessment
-
[14] Egan, A.G., Blind, E., Dunder, K., de Graeff, P.A., Hummer, B.T., Bourcier, T., et al. Pancreatic safety of incretin-based drugs—FDA and EMA assessment. N Engl J Med 370 (2014), 794–797.
-
(2014)
N Engl J Med
, vol.370
, pp. 794-797
-
-
Egan, A.G.1
Blind, E.2
Dunder, K.3
de Graeff, P.A.4
Hummer, B.T.5
Bourcier, T.6
-
15
-
-
84874631463
-
GLP-1 based agents and acute pancreatitis: drug safety falls victim to the three monkey paradigm
-
[15] Gale, E.A., GLP-1 based agents and acute pancreatitis: drug safety falls victim to the three monkey paradigm. BMJ, 346, 2013, f1263, 10.1136/bmj.f1263.
-
(2013)
BMJ
, vol.346
, pp. f1263
-
-
Gale, E.A.1
-
16
-
-
84901926135
-
Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials
-
[16] Monami, M., Dicembrini, I., Mannucci, E., Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 24 (2014), 689–697.
-
(2014)
Nutr Metab Cardiovasc Dis
, vol.24
, pp. 689-697
-
-
Monami, M.1
Dicembrini, I.2
Mannucci, E.3
-
17
-
-
84960100350
-
Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies
-
[17] Li, L., Li, S., Deng, K., Liu, J., Vandvik, P.O., Zhao, P., et al. Dipeptidyl peptidase-4 inhibitors and risk of heart failure in type 2 diabetes: systematic review and meta-analysis of randomised and observational studies. BMJ, 352, 2016, i610, 10.1136/bmj.i610.
-
(2016)
BMJ
, vol.352
, pp. i610
-
-
Li, L.1
Li, S.2
Deng, K.3
Liu, J.4
Vandvik, P.O.5
Zhao, P.6
-
18
-
-
84930085787
-
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
-
[18] Zannad, F., Cannon, C.P., Cushman, W.C., Bakris, G.L., Menon, V., Perez, A.T., et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet 385 (2015), 2067–2076.
-
(2015)
Lancet
, vol.385
, pp. 2067-2076
-
-
Zannad, F.1
Cannon, C.P.2
Cushman, W.C.3
Bakris, G.L.4
Menon, V.5
Perez, A.T.6
-
19
-
-
84928699536
-
Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials
-
May
-
[19] Udell, J.A., Cavender, M.A., Bhatt, D.L., Chatterjee, S., Farkouh, M.E., Scirica, B.M., Glucose-lowering drugs or strategies and cardiovascular outcomes in patients with or at risk for type 2 diabetes: a meta-analysis of randomised controlled trials. Lancet Diabetes Endocrinol 3 (2015 May), 356–366.
-
(2015)
Lancet Diabetes Endocrinol
, vol.3
, pp. 356-366
-
-
Udell, J.A.1
Cavender, M.A.2
Bhatt, D.L.3
Chatterjee, S.4
Farkouh, M.E.5
Scirica, B.M.6
-
20
-
-
34548603259
-
Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review
-
[20] Eurich, D.T., McAlister, F.A., Blackburn, D.F., Majumdar, S.R., Tsuyuki, R.T., Varney, J., et al. Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review. Brit Med J, 335(7618), 2007, 497.
-
(2007)
Brit Med J
, vol.335
, Issue.7618
, pp. 497
-
-
Eurich, D.T.1
McAlister, F.A.2
Blackburn, D.F.3
Majumdar, S.R.4
Tsuyuki, R.T.5
Varney, J.6
-
21
-
-
0016251063
-
Role of diabetes in congestive heart failure: the Framingham study
-
[21] Kannel, W.B., Hjortland, M., Castelli, W.P., Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34 (1974), 29–34.
-
(1974)
Am J Cardiol
, vol.34
, pp. 29-34
-
-
Kannel, W.B.1
Hjortland, M.2
Castelli, W.P.3
-
22
-
-
0029893241
-
Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry
-
[22] Shindler, D.M., Kostis, J.B., Yusuf, S., Quinones, M.A., Pitt, B., Stewart, D., et al. Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. Am J Cardiol 77 (1996), 1017–1020.
-
(1996)
Am J Cardiol
, vol.77
, pp. 1017-1020
-
-
Shindler, D.M.1
Kostis, J.B.2
Yusuf, S.3
Quinones, M.A.4
Pitt, B.5
Stewart, D.6
-
23
-
-
0035810983
-
Glycemic control and heart failure among adult patients with diabetes
-
[23] Iribarren, C., Karter, A.J., Go, A.S., Ferrara, A., Liu, J.Y., Sidney, S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 103 (2001), 2668–2673.
-
(2001)
Circulation
, vol.103
, pp. 2668-2673
-
-
Iribarren, C.1
Karter, A.J.2
Go, A.S.3
Ferrara, A.4
Liu, J.Y.5
Sidney, S.6
-
24
-
-
84978839381
-
Liraglutide and cardiovascular outcomes in type 2 diabetes
-
[24] Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375 (2016), 311–322.
-
(2016)
N Engl J Med
, vol.375
, pp. 311-322
-
-
Marso, S.P.1
Daniels, G.H.2
Brown-Frandsen, K.3
Kristensen, P.4
Mann, J.F.5
Nauck, M.A.6
-
25
-
-
45149133036
-
Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes (ADVANCE)
-
[25] Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes (ADVANCE). N Engl J Med 358 (2008), 2560–2572.
-
(2008)
N Engl J Med
, vol.358
, pp. 2560-2572
-
-
-
26
-
-
79960959816
-
Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials
-
[26] Boussageon, R., Bejan-Angoulvant, T., Saadatian-Elahi, M., Lafont, S., Bergeonneau, C., Kassaï, B., et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. Brit Med J, 343, 2011, d4169, 10.1136/bmj.d4169.
-
(2011)
Brit Med J
, vol.343
, pp. d4169
-
-
Boussageon, R.1
Bejan-Angoulvant, T.2
Saadatian-Elahi, M.3
Lafont, S.4
Bergeonneau, C.5
Kassaï, B.6
-
27
-
-
84898614282
-
Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial
-
[27] Lincoff, A.M., Tardif, J.C., Schwartz, G.G., et al. Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial. JAMA 311 (2014), 1515–1525.
-
(2014)
JAMA
, vol.311
, pp. 1515-1525
-
-
Lincoff, A.M.1
Tardif, J.C.2
Schwartz, G.G.3
-
28
-
-
84946191506
-
Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?
-
[28] Bejan-Angoulvant, T., Cornu, C., Archambault, P., Tudrej, B., Audier, P., Brabant, Y., et al. Is HbA1c a valid surrogate for macrovascular and microvascular complications in type 2 diabetes?. Diabetes Metab 41 (2015), 195–201.
-
(2015)
Diabetes Metab
, vol.41
, pp. 195-201
-
-
Bejan-Angoulvant, T.1
Cornu, C.2
Archambault, P.3
Tudrej, B.4
Audier, P.5
Brabant, Y.6
|